Depletion Method Patent - Tecan Genomics (US12600963B2)
Summary
USPTO granted patent US12600963B2 to Tecan Genomics, Inc. covering methods and systems for selective amplification of cDNA during whole-transcriptome analysis. The technology uses primer sets incorporating tags and nucleotide analogs to deplete non-coding sequences such as ribosomal RNA, preventing their amplification while preserving desired transcript sequences.
What changed
USPTO issued patent US12600963B2 to Tecan Genomics, Inc. for methods of depleting abundant uninformative sequences during cDNA amplification. The patent covers techniques using different primer sets in reverse transcription to incorporate tags allowing selective amplification, including nucleotide analogs that prevent amplification of non-coding RNA sequences. The technology employs single primer isothermal amplification (SPIA) techniques for whole-transcriptome analysis applications.
Affected parties include biotech researchers, pharmaceutical developers, and diagnostic companies conducting gene expression analysis. While this patent does not create immediate compliance obligations, entities developing similar RNA depletion or transcriptome analysis technologies should review potential patent infringement risks and consider licensing discussions with Tecan Genomics.
What to do next
- Monitor for updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Depletion of abundant uninformative sequences
Grant US12600963B2 Kind: B2 Apr 14, 2026
Assignee
Tecan Genomics, Inc.
Inventors
Bin Li, Lin Pham
Abstract
The use of different primer sets in reverse transcription incorporates tags allowing for the selective amplification of cDNA transcribed using the different primers. Primers targeting non-desired RNA sequences such as ribosomal RNA can be used to prevent subsequent amplification of cDNA transcribed from those non-coding fragments. Accordingly effective depletion of non-desired sequences after cDNA amplification can be achieved. Systems and methods of the invention have applications in whole-transcriptome analysis. Non-coding sequence targeting primers can include nucleotide analogs that, when enzymatically processed, prevent subsequent amplification. Library preparation can include single primer isothermal amplification (SPIA) techniques wherein an RNA sequence required for SPIA is included in random primers but is absent from primers targeting non-coding RNA.
CPC Classifications
C12N 15/1096 C12Q 1/6853
Filing Date
2021-01-20
Application No.
17153019
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.